Verastem has entered the KRAS G12D lung cancer race, but can VS-7375 close the evidence gap?
Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.
Pharma & Biotech
Pharma & Biotech
Could Verastem Oncology’s KRAS G12D bet change the pancreatic cancer treatment race?
Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.
Pharma & Biotech
Does Verastem Oncology’s updated RAMP 201 dataset change the outlook for low-grade serous ovarian cancer treatment?
Verastem Oncology’s two-year ovarian cancer data strengthen the case for avutometinib plus defactinib. Read what this means next.
Pharma & Biotech
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.